MDGL - Galectin Therapeutics: Neutral On Belapectin For NASH Cirrhosis Amid Financial Challenges

2024-06-07 07:21:34 ET

Summary

• Galectin Therapeutics is focused on developing therapies that target galectin proteins related to conditions such as metabolic dysfunction-associated steatohepatitis, cirrhosis, and cancer.
• Its leading drug candidate, belapectin, is a galectin-3 inhibitor with promising results for treating NASH cirrhosis, a severe liver disease without an FDA-approved therapy.
• The company is researching potential new indications for belapectin in fibrosis in different organs and cancer immunotherapy.
• GALT's financial constraints include a high cash burn rate, significant debt, and a limited cash runway.
• Galectin's belapectin presents a significant market opportunity in cirrhosis but faces competitive and financial challenges, leading to a "hold" rating.

Galectin Therapeutics Inc. ( GALT ) is a biotechnology company focused on developing therapies that target galectin proteins related to conditions such as metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and cancer. Galectins, specifically galectin-3, are involved in inflammation, fibrosis, and tumor growth by binding to carbohydrates on cell surfaces, stimulating pathological disease processes. Thus, GALT's leading drug candidate, belapectin, is a galectin-3 inhibitor with promising results for treating NASH cirrhosis, a severe liver disease without an FDA-approved therapy....

For further details see: